Corbus Pharmaceuticals Holdings, Inc. reports clinical-stage drug-development news in oncology and obesity. Updates center on CRB-701, a next-generation Nectin-4 antibody-drug conjugate licensed from CSPC Megalith Biopharmaceutical, including data presentations in head and neck squamous cell carcinoma and cervical cancer, FDA interactions and Fast Track designations.
Company news also covers CRB-913, a peripherally restricted oral CB1 inverse agonist for obesity, and CRB-601, an anti-integrin monoclonal antibody targeting TGFβ activation. Recurring items include clinical trial disclosures, medical-meeting presentations, management conference appearances, governance changes and operating or financial results.
Rhea-AI Summary
Summary not available.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.86%
Tags
FAQ
What is the current stock price of Corbus Pharmaceuticals Holdings (CRBP)?
The current stock price of Corbus Pharmaceuticals Holdings (CRBP) is $6.13 as of October 3, 2026.
What is the market cap of Corbus Pharmaceuticals Holdings (CRBP)?
The market cap of Corbus Pharmaceuticals Holdings (CRBP) is approximately 118.6M.